Cellectis (Cellectis) Other Stockholders Equity

: $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Cellectis's Other Stockholders Equity for the quarter that ended in Sep. 2023 was $0.00 Mil.

Cellectis's quarterly Other Stockholders Equity increased from Mar. 2023 ($-0.00 Mil) to Jun. 2023 ($0.00 Mil) and increased from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Cellectis's annual Other Stockholders Equity declined from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($-0.00 Mil) but then increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($0.00 Mil).

Cellectis Other Stockholders Equity Historical Data

The historical data trend for Cellectis's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Stockholders Equity

Get a 7-Day Free Trial

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Cellectis Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Cellectis Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cellectis's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.